The Agreement will benefit both companies’ existing and potential clients with diverse product pipelines by combining CoreRx’s problem-solving and formulation/processing expertise in small molecules with Viropro’s reputation in the development and manufacturing of biopharmaceutical drugs.
Cynthia Tsai, Chairperson and Interim CEO of Viropro, Inc., said, “The agreement is another important step in Viropro’s push to build a global network committed to delivering solutions to advance new medicines. It will also leverage Viropro’s expertise to provide clients with optimized solutions to their biopharmaceutical development challenges.”
"We are pleased that we are going to continue to improve upon the technologies we are able to offer our clients," said Todd R. Daviau, CEO of CoreRx. "Since our inception, CoreRx has been working to meet the challenges of drug delivery and enhance the performance of our clients’ drugs. By addressing the needs of clients in biosimilar and large molecule development, CoreRx will continue to play a role in the development of drug candidates and the diversification of their pipelines."